STENTYS initiates enrollment in Self-Apposing Sirolimus-eluting stent trial for heart attack

STENTYS S.A. (STNT.PA), a medical technology company commercializing the world's first and only Self-Apposing® Stent to treat Acute Myocardial Infarction (AMI), announced today that it has enrolled the first patient in its 'APPOSITION IV' clinical study using its new Self-Apposing® Sirolimus-eluting stent. The randomized study will enroll 150 heart attack patients who will be treated with either the STENTYS stent or Medtronic's Resolute® drug-eluting stent, and will compare stent apposition in both groups at four and nine months after treatment.    

Conventional drug-eluting stents have shown a high rate of persistent malapposition several months after heart attack treatment. This malapposition can trigger stent re-clotting, recurrence of the heart attack and possible subsequent death years afterwards.

"Long-term malapposition of drug-eluting stents has been associated with late stent thrombosis, so this randomized trial with the new STENTYS sirolimus-eluting self-apposing stent will be carefully followed by the community," said Dr. William Wijns, co-principal investigator of the study and Chairman of EuroPCR.

"Following the excellent results from the APPOSITION III study, we are going to add the Sirolimus-eluting stent to our portfolio and combine the best stent platform with a proven drug from the 'limus' family," said Gonzague Issenmann, CEO and co-founder of STENTYS. "Cardiologists will have access to STENTYS stents eluting the two compound families available on the market."

The STENTYS Self-Apposing® Stent solves the stent-sizing dilemma that cardiologists are confronted with when treating heart attack patients with conventional stents. It "fits snugly" into the contour of a blood vessel, and its shape and diameter adapt as the vessel dilates and the initial clot dissolves during the post-AMI phase, eliminating malapposition and its major complications seen with all other conventional stents.    

Source:

STENTYS S.A.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Medtronic. (2019, June 18). STENTYS initiates enrollment in Self-Apposing Sirolimus-eluting stent trial for heart attack. News-Medical. Retrieved on July 18, 2024 from https://www.news-medical.net/news/20120615/STENTYS-initiates-enrollment-in-Self-Apposing-Sirolimus-eluting-stent-trial-for-heart-attack.aspx.

  • MLA

    Medtronic. "STENTYS initiates enrollment in Self-Apposing Sirolimus-eluting stent trial for heart attack". News-Medical. 18 July 2024. <https://www.news-medical.net/news/20120615/STENTYS-initiates-enrollment-in-Self-Apposing-Sirolimus-eluting-stent-trial-for-heart-attack.aspx>.

  • Chicago

    Medtronic. "STENTYS initiates enrollment in Self-Apposing Sirolimus-eluting stent trial for heart attack". News-Medical. https://www.news-medical.net/news/20120615/STENTYS-initiates-enrollment-in-Self-Apposing-Sirolimus-eluting-stent-trial-for-heart-attack.aspx. (accessed July 18, 2024).

  • Harvard

    Medtronic. 2019. STENTYS initiates enrollment in Self-Apposing Sirolimus-eluting stent trial for heart attack. News-Medical, viewed 18 July 2024, https://www.news-medical.net/news/20120615/STENTYS-initiates-enrollment-in-Self-Apposing-Sirolimus-eluting-stent-trial-for-heart-attack.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Medtronic: RCT demonstrates profound back pain relief with DTM therapy